| 尹 梅,田建宏,王海霞,罗 昆,李 华.双嘧达莫联合头孢呋辛对川崎病患儿WBC、PLT、ESR水平的影响[J].现代生物医学进展英文版,2020,(22):4323-4326. |
| 双嘧达莫联合头孢呋辛对川崎病患儿WBC、PLT、ESR水平的影响 |
| Effect of Dipyridamole Combined with Cefuroxime on WBC, PLT and ESR in Children with Kawasaki Disease |
| Received:February 27, 2020 Revised:March 23, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.22.027 |
| 中文关键词: 双嘧达莫 头孢呋辛 川崎病 抗血小板聚集相关因子 血清炎症因子 |
| 英文关键词: Dipyridamole Cefuroxime Kawasaki Disease Anti Platelet Aggregation Related Factors Serum Inflammatory Factors |
| 基金项目:陕西省重点研发计划项目（2019SF-207） |
|
| Hits: 570 |
| Download times: 402 |
| 中文摘要: |
| 摘要 目的：研究双嘧达莫联合头孢呋辛对川崎病患儿白细胞（white blood cell，WBC）、血小板（blood platelet，PLT）、红细胞沉降率(erythrocyte sedimentation rate，ESR)水平的影响。方法：选择2015年1月～2019年12月我院（西安交通大学附属儿童医院）收治的71例川崎病患儿，随机分为两组。对照组服用头孢呋辛治疗，每次10 mg／kg，每天2次，持续给药14 d或直至患儿退热后7 d为止。观察组在头孢呋辛的基础上，加服双嘧达莫，剂量为每天3～5 mg/kg，分成3次服用，持续给药两个月。检测两组治疗前后的抗血小板聚集相关因子和血清炎症因子的变化。结果：观察组川崎病患儿的有效率明显高于对照组(P<0.05)；治疗后，两组患儿的WBC、PLT和ESR水平均明显降低(P<0.05)，且观察组患儿的WBC、PLT和ESR水平明显低于对照组(P<0.05)；观察组川崎病患儿颈淋巴结肿胀、发热、黏膜弥漫性充血、结膜充血、躯干红斑等症状的缓解时间均明显短于对照组(P<0.05)；治疗后，两组患儿的血清H血清高迁移率族蛋白B1（High mobility group protein B1，HMGB1）、肿瘤坏死因子（Tumor necrosis factor，TNF）-α、巨噬细胞移动抑制因子（Macrophage migration inhibitory factor，MIF）和白介素-6（Interleukin -6，IL-6）水平均明显降低(P<0.05)，且观察组患儿的血清HMGB1、TNF-α、MIF和IL-6水平明显低于对照组(P<0.05)。结论：双嘧达莫联合头孢呋辛能有效抑制川崎病患儿的血小板聚集，提高治疗有效率，降低炎性因子水平，减轻临床症状，值得推广。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of dipyridamole combined with cefuroxime on white blood cell (WBC), platelet (PLT), erythrocyte sedimentation rate (ESR) in children with Kawasaki disease. Methods: Selected 71 cases of patients with Kawasaki disease who were treated in our hospital from January 2015 to December 2019, divided into two groups randomly. The control group was treated with clarithromycin 10 mg/kg twice a day for 14 days or until 7 days after fever abatement. In the observation group, dipyridamole was added on the basis of clarithromycin at a dose of 3-5 mg/kg per day, which was divided into three times for two months. The changes of anti-platelet aggregation related factors and serum inflammatory factors were detected before and after treatment. Results: The effective rate of children with Kawasaki disease in the observation group was significantly higher than that in the control group (P<0.05). After treatment, WBC, PLT and ESR levels of the two groups were significantly reduced (P<0.05), the levels of WBC, PLT and ESR in the observation group were significantly lower than those in the control group (P<0.05). The relief time of cervical lymph node swelling, fever, diffuse congestion of mucous membrane, conjunctival congestion and erythema of trunk in the observation group was significantly shorter than that in the control group(P<0.05). After treatment, the levels of HMGB1, TNF-α, MIF and IL-6 in serum of the two groups decreased significantly(P<0.05), The serum levels of HMGB1, TNF-α, MIF and IL-6 in the observation group were significantly lower than those in the control group (P<0.05). Conclusion: Dipyridamole combined with cefuroxime can effectively inhibit the platelet aggregation of children with Kawasaki disease, improve the treatment efficiency, reduce the level of inflammatory factors, reduce the clinical symptoms, which is worth promoting. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
